DEP says Maine beaches cleanest in years

12:56 PM

By Eric Russell erussell@pressherald.com Staff Writer

Public beaches along Maines coastline likely will be flooded with visitors this weekend as temperatures are expected to creep into the 90s.

click image to enlarge

More than two-thirds of the 61 beaches monitored by the DEP had no water quality issues in 2011, an improvement from 2010, when almost half of all beaches had at least one advisory.

John Patriquin / Staff Photographer

The ocean water at those 61 beaches, which collectively stretch more than 30 miles, will be the cleanest and safest it has been in four years, according to data released by the Maine Department of Environmental Protection.

The Maine Healthy Beaches program monitors recreational water quality as a way to protect public health. Its funded by the federal Environmental Protection Agency and receives staff support from the University of Maine Cooperative Extension/Sea Grant.

From Memorial Day through Labor Day, water samples are analyzed every week for the enterococcus bacteria, which indicates the presence of fecal contamination from humans and animals. If bacteria levels exceed limitations sets by the EPA, beach managers will post an advisory. If levels are extremely high, beaches have to be closed.

Last year, the program found that beach advisory days had declined by nearly 50 percent from the previous summer. More than two-thirds of the 61 beaches had no water quality issues in 2011, an improvement from 2010, when almost half of all beaches had at least one advisory.

More here:

DEP says Maine beaches cleanest in years

Guide to the best beaches in Maui

Maui is called The Valley Island, but in most travelers minds, its beaches are synonymous with the Hawaiian island. In the annual Best Beach contest held since 1991, Maui has won four times five, if you stretch the definition of Maui. Maui County includes the islands of Molokai and Lanai, and a beach on Lanai won in 1997.

And Maui isnt done. A remote beach in an area once favored by Oprah Winfrey made this years Top 10 and is likely to win the top spot eventually.

Its not all good news for Maui. A U.S. Geological Survey report says Maui has the highest rate of beach erosion in the state. Data from 1899 to 2007 show Maui beaches averaged 6.7 inches of sand lost each year. The worst impact is on the north shore near Paia. Erosion rates are somewhat higher in the Kaanapali area than in Kihei or Wailea.

As to the rankings, Ive criticized the methodology of the contest put out each spring by Dr. Beach, Stephen Leatherman, a Florida oceanography professor. He has a big East Coast bias, but we cant argue with his favorites in Maui. Here are the big ones, along with the next champion in waiting. The year the beach won the contest is in parentheses.

D.T. Fleming Beach Park, Maui (2006): Ive taken my share of knocks at this great bodysurfing beach on the sometimes turbulent northwest shore of Maui. When youre feeling a bit winded from battling the waves, there are shade trees along parts of the mile-long strand. When you are ready to call it a day, head uphill to the bar at the Ritz-Carlton for some sundowner drinks and pupus.

Kaanapali, Maui (2003): The busiest beach on this list, its fronted by a string of hotels from the Sheraton on the north to the Hyatt on the south and the Whalers Village shopping mall in the middle. With all the fancy resort swimming pools, guests sometimes forget that a world-class beach is just on the other side of the walkway. Theres usually gentle surf and knockout views toward Lanai. My favorite spot is Black Rock at the north end of the beach, with its excellent snorkeling and the crazies jumping off the rock.

Wailea Beach, Maui (1999): Wider, hotter and less crowded than Kaanapali to the north, Wailea is also fronted by luxury hotels and rocks in portions, but wide sands in other areas. The drop-off is gradual here, making it good for kids if the waves arent up. The view here is also outstanding, with views toward the tiny Molokini crater dive spot and the island of Kahoolawe, once used for Navy target practice.

Kapalua Bay Beach, Maui (1991): The first best-beach on Leathermans list is still one of the islands prettiest, though in the intervening decades, development has taken over the slope just above the beach, replacing palm trees and greenery with hotel and condo units. Though it has lost some of its magic, the beach itself is still a beautiful crescent of blond-colored sand fronting clear aquamarine waters.

Hulopoe, Lanai (1997): Lanai is officially part of Maui County, governed from the Maui town of Wailuku. If you want to get political, it could be included in Mauis best-beach count. Theres actually a geological basis for inclusion with the other beaches. Lanai and Molokai were once part of Maui Nui, the massive, ancient volcanic island that collapsed into the sea millions of years ago. Hulopoe is the best beach in the Hawaiian islands that barely anyone gets to. Its next to the Four Seasons Manele Bay on the former pineapple plantation island. There are trees for shade and picnic tables for get-togethers, and a nice mix of tourists and locals.

Hamoa Beach (No. 5 in 2012): Travelers really, really have to want to visit this beach. Its just beyond the Travaasa Resort at the end of the twisting, 52-mile Hana Highway from Kahului. The beach is framed by coconut palm trees that give shade on hot days. The beach is actually the side of an old volcanic crater. The area has been a favored getaway for celebrities for nearly a century. Aviator Charles Lindbergh is buried in a churchyard nearby, writer Ernest Hemingway called it one of the most beautiful beaches hed seen, ex-Beatle George Harrison lived not far away, and TV host-magnate Oprah Winfrey owns property on this side of the island, although her main residence is now upcountry near Kula. If all goes according to the trend, Hamoa should reach the No. 1 designation later this decade.

Follow this link:

Guide to the best beaches in Maui

Cannonball star blasts away from the scene of the crime | Bad Astronomy

When I picture an exploding star in my head which I do unsurprisingly often the imaginary mental detonation I picture is symmetric. That is, it expands like a sphere, getting bigger in all directions equally.

Supernovae are actually not like that though. Stars are messy affairs, and when massive ones explode they tend to have internal factors that distort that nice, smooth expansion. One big factor is that the actual point of explosion is off-center in the star, not at its exact heart. That can create a massively asymmetric explosion, blasting vast amounts of material and energy off to one side.

Mind you, the core itself in such a star still collapses to become a super-dense neutron star (or a black hole), but the sideways nature of the explosion can give a kick to the leftover ball of neutrons. Quite a kick. In fact, the energies are so titanic that an off-center supernova explosion can blast the neutron star in the other direction, screaming away from the explosion site like a shell out of the muzzle of a battleship gun.

And now astronomers may have found the most extreme example of this: what looks to be just such a neutron star barreling away from a supernova at high speed:

[Click to Chandrasekharenate.]

This image is a combination of observations from the XMM-Newton and Chandra X-ray observatories, the Digitized Sky Survey, and the 2MASS infrared survey. It shows the supernova remnant SNR MSH 11-16A, located about 30,000 light years away. The purple glow is from X-rays emitted by the gas superheated to millions of degrees by the exposion.

But look off to the right. See that comet-looking thing? Ive put a close up of it here. You can see a dot at the head of the "comet": astronomers think that might be the runaway neutron star from the explosion that created SNR MSH 11-16A! Its hard to know for sure, but a lot of things add up to make me think theyre right.

The most obvious is that tail of gas pointing right back to the center of the supernova gas cloud. A hot, young neutron star blows out a high-energy wind of subatomic particles called a pulsar wind, and that pushes against gas floating out in space. As a runaway neutron star blasts through space, it would leave a glowing trail like that. The X-rays appear to be coming from a single, tiny point, just what youd expect for a neutron star, and observations using optical and infrared dont see it; again, just what youd expect since neutron stars are tiny and dont glow visibly. Theyre brightest in X-rays due to their phenomenally strong magnetic fields whipping particles around at high energies.

The fainter tail to the side is something of a mystery, though. Apparently things like this have been seen before, but its not clear whats causing it.

Read more here:

Cannonball star blasts away from the scene of the crime | Bad Astronomy

Accelerated Radiation Treatment Effective for Noninvasive Breast Cancer

Treatment time for this common cancer could be cut in half

Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation OncologyBiologyPhysics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

The widespread use of mammography beginning in the early 1980s has led to a dramatic increase in the number of DCIS instances detected, making this one of the most common forms of breast cancer. Multiple studies have proven that lumpectomy plus radiation significantly reduces the risk of recurrence in both noninvasive and invasive breast cancers and for DCIS, the current standard of treatment is lumpectomy followed by five to six weeks of whole breast radiation.

However, for invasive cancers, the use of an accelerated form of radiation that increases the strength of the dose per treatment and uses fewer treatment sessions overall has been well-established as effective, providing patients with a shorter treatment time with similar positive results. The effectiveness of an accelerated treatment time has not been established for DCIS.

Researchers in the study followed 145 DCIS patients who were treated with lumpectomy and accelerated whole breast irradiation or lumpectomy with accelerated whole breast irradiation plus an additional daily boost. At five years post-treatment, only 4.1 percent of patients experienced a recurrence, which is comparable to the five to 10 percent recurrence rate demonstrated in randomized trials for patients receiving standard radiation.

The results of our study suggest that DCIS patients can be safely treated with a shorter regimen of radiotherapy, Silvia Formenti, MD, senior author of the study and a radiation oncologist at New York University School of Medicine, said. This is good news for many breast cancer patients who would prefer to receive their treatments in a shorter period of time, but also want the peace of mind that they are receiving the most effective treatment available.

ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. For more information on radiation therapy, visit http://www.rtanswers.org. To learn more about ASTRO, visit http://www.astro.org. ###

Go here to see the original:

Accelerated Radiation Treatment Effective for Noninvasive Breast Cancer

Lanka to lead Nanotechnology research and development

Ramani KANGARAARACHCHI

Sri Lanka will be positioned as a leading destination for Nanotechnology research and development contributing significantly to national economic development with the completion of Sri Lanka Institute of Nanotechnology (SLINTEC),Chairman SLINTEC Mahesh Amalean said.

Speaking at the foundation laying ceremony for the construction of the Nanotechnology Centre of Excellence(NCE) at Homagama yesterday Amalean said the investment for the initial stage of the project is Rs 830 million.

Chairman SLINTEC, Mahesh Amalean, Minister of Technology and Research, Pavithra Wanniarachchi and Minister of Science and Technology, Prof. Tissa Vitarana at the ground breaking event.

He said this is a unique project in a land allocated by the government and funded through public private partnership where Brandix, Hayleys, Load Star, MAS, Dialogue and Virtusa join hands with the Ministry of Technology and Research. The nanotechnology park will enable companies to invest and develop their research centres incubation facilities and pilot plants in an environment of an advanced technology park.

The project will develop a 50 acre land with a state of the art NCE in Pitipana, Homagama in a phased manner through pragmatic investments by all interested parties. It aims to attract research and development institutes, multinational companies, small and medium enterprises and education institutes to take advantage of the research ,development and innovation that will flourish in the enterprising ecosystem created at this advanced technology park. It will have a series of high tech labs with the latest equipment operated and managed by highly skilled scientists. The project will focus on R and D ,incubation for taking research into commercialization and provide facilities for corporate research and business development. Leading experts from around the globe will have tenures at the NCE and they will be available for consultation to continue with boundaries of innovation, he said.

The second phase of the park will focus on expansion of research and business development for both the public and private sector in Sri Lanka and potential foreign direct investment from multi national corporations as well as SMEs through attractive incentives, terms and conditions.

Follow this link:
Lanka to lead Nanotechnology research and development

Easter Island drug raises cognition throughout life span

Public release date: 29-Jun-2012 [ | E-mail | Share ]

Contact: Will Sansom sansom@uthscsa.edu 210-567-2579 University of Texas Health Science Center at San Antonio

SAN ANTONIO, Texas, U.S.A. (June 29, 2012) -- Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots.

The researchers, appointed in the School of Medicine at The University of Texas Health Science Center San Antonio, added rapamycin to the diet of healthy mice throughout the rodents' life span. Rapamycin, a bacterial product first isolated from soil on Easter Island, enhanced learning and memory in young mice and improved these faculties in old mice, the study showed.

"We made the young ones learn, and remember what they learned, better than what is normal," said Veronica Galvan, Ph.D., assistant professor of physiology at the Barshop Institute for Longevity and Aging Studies, part of the UT Health Science Center. "Among the older mice, the ones fed with a diet including rapamycin actually showed an improvement, negating the normal decline that you see in these functions with age."

The drug also lowered anxiety and depressive-like behavior in the mice, Dr. Galvan said. Anxiety and depression are factors that impair human cognitive performance. Lead author Jonathan Halloran conducted scientifically reliable tests to accurately measure these cognitive components in the rodents.

Venturing into the open

Mice are burrowers that prefer tunnels with walls. To observe behavior, Halloran used an elevated maze of tunnels that led to a catwalk. "All of a sudden the mice are in open space," Halloran said. "It's pretty far from the floor for their size, sort of like if a person is hiking and suddenly the trail gets steep. It's pretty far down and not so comfortable."

Mice with less anxiety were more curious to explore the catwalk. "We observed that the mice fed with a diet containing rapamycin spent significantly more time out in the open arms of the catwalk than the animals fed with a regular diet," Halloran said.

The second test measured depressive-like behavior in the rodents. Mice do not like to be held by their tails, which is the way they are moved from cage to cage. Inevitably they struggle to find a way out. "So we can measure how much and how often they struggle as a measure of the motivation they have to get out of an uncomfortable situation," Dr. Galvan said.

Continue reading here:
Easter Island drug raises cognition throughout life span

REGION: Alternative medicine going to the dogs

Nine-year-old Dewey rested her head in Sharon Cerkan's lap as the doctor poked a series of needles into her damaged hip.

Cerkan kept Dewey calm as electrical currents charged through the pins and shot into muscle. Some 25 minutes later, after the acupuncture session had ended, Dewey rose without hesitation and ran off to the family van.

Dewey, a Chesapeake Bay retriever/black Labrador mix who lives with Cerkan and her husband, Dan, in Carlsbad, is among the growing number of pets in America being treated with everything from acupuncture to herbal therapy for ailments and diseases that traditional medicine has failed to cure.

"It's becoming more mainstream, and the reason it's becoming more mainstream is it's effective," said Dr. Kathy Boehme, a veterinarian and partner at The Drake Center for Veterinary Care on El Camino Real in Encinitas, where Dewey goes for acupuncture treatments every three weeks.

Boehme calls the strategies used at her clinic integrative medicine. "We're integrating Eastern medicine with Western medicine," she said earlier this month.

Figures are unavailable, but veterinarians who practice alternative medicine say business is booming. A growing number of veterinary schools, including those at Colorado State, Louisiana State and the University of Florida, incorporate integrative medicine into their programs.

"Our membership has grown substantially over the years," said Simon Flynn, the American Academy of Veterinary Acupuncture's executive director. The group now has 825 licensed veterinarians.

"People want every advantage brought to their animal that they can find," he said.

Susan Wynn, president of the American Academy of Veterinary Acupuncture and the former president of the American Holistic Veterinary Medical Association, said more people are accepting alternative care for their pets because more people are open to alternative care for themselves.

She added that people often seek alternatives "because scientifically proven medicine has failed them."

Originally posted here:
REGION: Alternative medicine going to the dogs

Camelot eyes horse racing immortality

Aiden O'Brien's Camelot could become only the 16th horse to win the Epsom Derby and Irish Derby.

STORY HIGHLIGHTS

(CNN) -- This Saturday, Aiden O'Brien's unbeaten colt Camelot will be aiming to add the Irish Derby to his Epsom Derby victory from earlier this month. It's a neat double, achieved by only 15 horses before him. But his trainer has his eye on another prize.

Camelot has already captured the English 2,000 Guineas and the Epsom Derby. Assuming everything goes to plan this weekend, his next target will be the St. Ledger Stakes at Doncaster in September -- and racing immortality.

For Camelot stands on the brink of that rarest of achievements, the English "Triple Crown" of thoroughbred racing.

Royal regulations for Ascot's fashionistas

Only 15 horses have ever done the treble in the century and a half in which the 2,000 Guineas, Epsom Derby and St. Ledger Stakes have been run.

Three of those, wartime winners Pommern, Gay Crusader and Gainsborough will forever have an asterisk next to their names as racing was considered too disrupted in that period for their achievements to stand, making the "official" figure as low as 12.

The last Triple Crown winner was the great Nijinsky, way back in 1970 (although the brilliant filly Oh So Sharp did win the "Fillies' Triple Crown" -- the 1,000 Guineas, the Epsom Oaks and the St. Ledger -- in 1985).

Few horses these days even attempt the full set. Since Nijinsky (who, incidentally, also won the Irish Derby en route to his treble), only two other horses have won both the 2,000 Guineas and the Derby, and both of those -- Nashwan (1989) and Sea The Stars (2009) -- opted for a tilt at the Prix de l'Arc de Triomphe instead of the St. Ledger.

View original post here:
Camelot eyes horse racing immortality

Hamilton Thorne Showcases Two New Products for Fertility Clinics at ESHRE 2012

BEVERLY, MA and TORONTO--(Marketwire -06/29/12)- Hamilton Thorne Ltd. (HTL.V), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that the Company will be showcasing two of its premier clinical products at the 28th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) taking place in Istanbul, Turkey from July 1-4, 2012. Hamilton Thorne will be demonstrating its new IMSI-Strict imaging and analysis software and the FDA cleared and CE marked Multi-Pulse software at the Company's ESHRE booth # B19.

During the conference, Hamilton Thorne will announce the official commercial launch of its much anticipated IMSI-Strict imaging and analysis software. IMSI-Strict is the only automated software solution for live sperm morphology analysis under high magnification. IMSI-Strict combines Tygerberg Strict Criteria with motile sperm organelle morphology examination (MSOME) and provides software-based categorization using head size, head shape, mid-piece, and number of vacuoles. Using these analyzed parameters, sperm are assigned to one of three easy-to-determine categories: normal, sub-normal or abnormal.

Benefits of IMSI-Strict Software:

The Company will also highlight its Multi-Pulse software that recently received FDA clearance and a CE mark for performing embryo biopsy in clinical settings. The Multi-Pulse software comes standard with Hamilton Thorne's LYKOS clinical laser system, and provides rapid, repeated firing of the laser to facilitate removal of cells from an embryo during the trophectoderm biopsy process. Trophectoderm biopsy is considered one of the best methods used to remove cells from the embryos of patients undergoing pre-implantation genetic diagnosis (PGD) to screen for genetic disease or aneuploidy. The significant advantage of Multi-Pulse is that one press of the remote footswitch initiates multiple laser pulses in rapid succession for fast and easy cell separation, thereby limiting the amount of time the embryo spends outside the incubator.

"We are proud to officially launch the commercial availability of our IMSI Strict image and analysis system, the Company's best-in-class sperm morphology analysis product, as well as showcase our new Multi-Pulse software during this renowned fertility conference," said David Wolf, President and Chief Executive Office of Hamilton Thorne, Ltd. "With both Hamilton Thorne products on the market, we are providing clinicians with advanced and precise tools to dramatically increase successful fertility outcomes and enable important clinical procedures such as embryo biopsy."

Currently available in Europe for clinical procedures, IMSI-Strict is only available in the United States for research use, and not to be used for diagnostic purposes. In addition to IMSI-Strict and Multi-Pulse, Hamilton Thorne will be displaying the entire clinical laser product line at ESHRE, including our new LYKOS laser system. To view Hamilton Thorne's premier fertility products that will be on display at ESHRE, please click on this link for a highlights video: http://youtu.be/JqsQCIk8osA.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and development biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

See original here:
Hamilton Thorne Showcases Two New Products for Fertility Clinics at ESHRE 2012

Biology's Master Programmers

Photographs by Mark Ostow

George Church is an imposing figureover six feet tall, with a large, rectangular face bordered by a brown and silver nest of beard and topped by a thick mop of hair. Since the mid-1980s Church has played a pioneering role in the development of DNA sequencing, helpingamong his other achievementsto organize the Human Genome Project. To reach his office at Harvard Medical School, one enters a laboratory humming with many of the more than 50 graduate students and postdoctoral fellows over whom Church rules as director of the school's Center for Computational Genetics. Passing through an anteroom of assistants, I find Church at his desk, his back to me, hunched over a notebook computer that makes him look even larger than he is.

Church looms especially large these days because of his role as one of the most influential figures in synthetic biology, an ambitious and radical approach to genetic engineering that attempts to create novel biological entitieseverything from enzymes to cells and microbesby combining the expertise of biology and engineering. He and his lab are credited with many of the advances in harnessing and synthesizing DNA that now help other researchers modify microrganisms to create new fuels and medical treatments. When I ask Church to describe what tangible impact synthetic biology will have on everyday life, he leans back in his chair, clasps his hands behind his head, and says, "It will change everything. People are going to live healthier a lot longer because of synthetic biology. You can count on it."

Such grandiosity is not uncommon among the practitioners of synthetic biology. Ever since Church and a few other researchers began to combine biology and engineering a dozen years ago, they have promised it would "change everything." And no wonder. The very idea of synthetic biology is to purposefully engineer the DNA of living things so that they can accomplish tasks they don't carry out in nature. Although genetic engineering has been going on since the 1970s, a rapid drop in the cost of decoding and synthesizing DNA, combined with a vast increase in computer power and an influx into biology labs of engineers and computer scientists, has led to a fundamental change in how thoroughly and swiftly an organism's genetics can be modified. Church says the technology will eventually lead to all manner of breakthroughs: we will be able to replace diseased tissues and organs by reprogramming cells to make new ones, create novel microbes that efficiently secrete fuels and other chemicals, and fashion DNA switches that turn on the right genes inside a patient's cells to prevent arteries from getting clogged.

Even though some of these applications are years from reality, Church has a way of tossing off such predictions matter-of-factly. And it's easy to see why he's optimistic. The cost of both decoding DNA and synthesizing new DNA strands, he has calculated, is falling about five times as fast as computing power is increasing under Moore's Law, which has accurately predicted that chip performance will double roughly every two years. Those involved in synthetic biology, who often favor computer analogies, might say it's becoming exponentially easier to read from, and write into, the source code of life. These underlying technology trends, says Church, are leading to an explosion in experimentation of a sort that would have been inconceivable only a few years ago.

Up to now, it's proved stubbornly difficult to turn synthetic biology into a practical technology that can create products like cheap biofuels. Scientists have found that the "code of life" is far more complex and difficult to crack than anyone might have imagined a decade ago. What's more, while rewriting the code is easier than ever, getting it right isn't. Researchers and entrepreneurs have found ways to coax bacteria or yeast to make many useful compounds, but it has been difficult to optimize such processes so that the microbes produce significant quantities efficiently enough to compete with existing commercial products.

Church is characteristically undeterred. At 57, he has survived cancer and a heart attack, and he suffers from both dyslexia and narcolepsy; before I visited him, one of his colleagues warned that I shouldn't be surprised if he fell asleep on me. But he has founded or taken an advisory role in more than 50 startup companiesand he stayed awake throughout our time together, apparently excited to describe how his lab has found ways to take advantage of ultrafast sequencing and other tools to greatly speed up synthetic biology. Among its many projects, Church's lab has invented a technique for rapidly synthesizing multiple novel strings of DNA and introducing them simultaneously into a bacterial genome. In one experiment, researchers created four billion variants of E. coli in a single day. After three days, they found variants of the bacteria in which production of a desired chemical was increased fivefold.

The idea, Church explains, is to sort through the variations to find "an occasional hopeful monster, just as evolution has done for millions of years." By mimicking in lab experiments what takes eons in nature, he says, he is radically improving the odds of finding ways to make microbes not just do new things but do them efficiently.

A DNA Turn-On

In some ways, the difficulties researchers have faced making new, more useful life forms shouldn't come as a surprise. Indeed, a lesson of genome research over the last few decades is that no matter how elegantly compact the DNA code is, the biology it gives rise to is consistently more complex than anyone anticipated. When I began reporting the early days of gene discovery 30 years ago, biologists, as they often do, thought reductively. When they found a gene involved in disease, the discovery made headlines. Scientists said they believed that potent new medicines could soon deactivate malfunctioning versions of genes, or that gene therapy could be used to replace them with healthy versions in the body.

Read more:
Biology's Master Programmers

Study Finds New Gene Mutations That Lead to Enlarged Brain Size, Cancer, Autism, Epilepsy

Newswise SEATTLE June 28, 2012 A research team led by Seattle Childrens Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly. Mutations in three genes, AKT3, PIK3R2 and PIK3CA, were also found to be associated with a constellation of disorders including cancer, hydrocephalus, epilepsy, autism, vascular anomalies and skin growth disorders. The study, De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes, was published online June 24 in Nature Genetics.

The discovery offers several important lessons and hope for the future in medicine. First, the research team discovered additional proof that the genetic make-up of a person is not completely determined at the moment of conception. Researchers previously recognized that genetic changes may occur after conception, but this was believed to be quite rare. Second, discovery of the genetic causes of these human diseases, including developmental disorders, may also lead directly to new possibilities for treatment.

AKT3, PIK3R2 and PIK3CA are present in all humans, but mutations in the genes are what lead to conditions including megalencephaly, cancer and other disorders. PIK3CA is a known cancer-related gene, and appears able to make cancer more aggressive. Scientists at Boston Childrens Hospital recently published similar findings related to PIK3CA and a rare condition known as CLOVES syndrome in the American Journal of Human Genetics.

Physician researcher James Olson, MD, PhD, a pediatric cancer expert at Seattle Childrens and Fred Hutchinson Cancer Research Center who was not affiliated with the study, acknowledged the two decades-worth of work that led to the findings. This study represents ideal integration of clinical medicine and cutting-edge genomics, he said. I hope and believe that the research will establish a foundation for successfully using drugs that were originally developed to treat cancer in a way that helps normalize intellectual and physical development of affected children. The team knocked it out of the park by deep sequencing exceptionally rare familial cases and unrelated cases to identify the culprit pathway. The genes AKT3, PIK3R2 and PIK3CAall encode core components of the phosphatidylinositol-3-kinase (P13K)/AKT pathway, the culprit pathway referenced by Olson.

The research provides a first, critical step in solving the mystery behind chronic childhood conditions and diseases. At the bedside, children with these conditions could see new treatments in the next decade. This is a huge finding that provides not only new insight for certain brain malformations, but also, and more importantly, provides clues for what to look for in less severe cases and in conditions that affect many children, said William Dobyns, MD, a geneticist at Seattle Childrens Research Institute. Kids with cancer, for example, do not have a brain malformation, but they may have subtle growth features that havent yet been identified. Physicians and researchers can now take an additional look at these genes in the search for underlying causes and answers.

Researchers at Seattle Childrens Research Institute will now delve more deeply into the findings, with an aim to uncover even more about the potential medical implications for children. Based on what weve found, we believe that we can eventually reduce the burden of and need for surgery for kids with hydrocephalus and change the way we treat other conditions, including cancer, autism and epilepsy, said Jean-Baptiste Rivire, PhD, at Seattle Childrens Research Institute. This research truly helps advance the concept of personalized medicine.

Drs. Dobyns, Rivire and team made this discovery through exome sequencing, a strategy used to selectively sequence the coding regions of the genome as an inexpensive but effective alternative to whole genome sequencing. An exome is the most functionally relevant part of a genome, and is most likely to contribute to the phenotype, or observed traits and characteristics, of an organism.

BACKGROUND ON RESEARCHERS

Seattle Childrens Research Institute conducted this study in collaboration with teams from University of Washington Genome Sciences Department, FORGE (Finding of Rare Disease Genes) Canada Consortium, Cedars Sinai Medical Center and University of Sussex.

Dr. Dobyns, who is also a UW professor of pediatrics, is a renowned researcher whose life-long work has been to try to identify the causes of childrens developmental brain disorders such as megalencephaly. He discovered the first known chromosome abnormality associated with lissencephaly (Miller-Dieker syndrome) while still in training in child neurology at Texas Childrens Hospital in 1983. That research led, 10 years later, to the discovery by Dobyns and others of the first lissencephaly gene known as LIS1.

Continue reading here:
Study Finds New Gene Mutations That Lead to Enlarged Brain Size, Cancer, Autism, Epilepsy

New gene therapy for smoking kills the pleasure of nicotine

Cant kick cigarettes? A vaccine may one day help by preventing nicotine from reaching its target in the brain, according to research published this week.

Most smoking therapies do a poor job of stopping the habit 70% to 80% of smokers who use an approved drug therapy to quit relapse. Scientists say this is because the targets of existing therapies are imperfect, only slightly weakening nicotines ability to find its target in the brain.

So some scientists have been trying a different approach creation of a vaccine. It would work like this: People would inject the vaccine like a shot, and the vaccine would create nicotine antibodies, molecules that can snatch up nicotine from the bloodstream before it reaches the brain. The vaccine could be used by smokers who want to quit or people who are worried about getting addicted to cigarettes in the future.

Researchers have tried to create vaccines in the past, but the ones theyve come up with have not been particularly effective. The authors of the new study say this may be because previous vaccines just didnt create enough antibodies to get rid of all the nicotine.

The new report, published in the journal Science Translational Medicine, attempts to solve this problem via gene therapy, in which a new gene is inserted into the body to do a particular job.

First the scientists at Weill Cornell Medical College in New York City put a gene that produces a nicotine antibody into mice. The gene was taken into the mices livers, and the liver started producing the antibody. Once produced, the antibody connected with nicotine, trapping it and preventing it from making its way to the brain, where it would otherwise have caused the pleasurable, addictive effects it is so known for.

Because of this trick, the researchers say that the new vaccine should only have to be injected once, and it will work for life, continuing to produce new antibodies in the liver.

The vaccine was effective: When mice were given nicotine intravenously, ones with the vaccine had a 47-fold drop in levels of nicotine in the blood compared with ones that hadnt received the vaccine. The antibody had successfully captured the nicotine in the bloodstream before it could reach the brain.

The work is still preliminary, and the authors admit the technology is far from ready for human use; it has only been used in rodents so far. But given the results, and the continued public health effect of smoking, it may not be too long before all those boxes of Nicorette are replaced with a single trip to the doctors office.

Read more:
New gene therapy for smoking kills the pleasure of nicotine

BUSM researchers identify role of FOXO1 gene in Parkinson's disease

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Jenny Eriksen Leary jenny.eriksen@bmc.org 617-638-6841 Boston University Medical Center

(Boston) A recent study led by researchers at Boston University School of Medicine (BUSM) revealed that the FOXO1 gene may play an important role in the pathological mechanisms of Parkinson's disease. These findings are published online in PLoS Genetics, a peer-reviewed open-access journal published by the Public Library of Science.

The study was led by Alexandra Dumitriu, PhD, a postdoctoral associate in the department of neurology at BUSM. Richard Myers, PhD, professor of neurology at BUSM, is the study's senior author.

According to the Parkinson's Disease Foundation, 60,000 Americans are diagnosed with Parkinson's disease each year and approximately one million Americans are currently living with the disease.

Parkinson's disease is a complex neurodegenerative disorder characterized by a buildup of proteins in nerve cells that lead to their inability to communicate with one another, causing motor function issues, including tremors and slowness in movement, as well as dementia. The substantia nigra is an area of the midbrain that helps control movement, and previous research has shown that this area of the brain loses neurons as Parkinson's disease progresses.

The researchers analyzed gene expression differences in brain tissue between 27 samples with known Parkinson's disease and 26 samples from neurologically healthy controls. This data set represents the largest number of brain samples used in a whole-genome expression study of Parkinson's disease to date. The novel aspect of this study is represented by the researchers' emphasis on removing possible sources of variation by minimizing the differences among samples. They used only male brain tissue samples that showed no significant marks of Alzheimer's disease pathology, one of the frequently co-occurring neurological diseases in Parkinson's disease patients. The samples also had similar tissue quality and were from the brain's prefrontal cortex, one of the less studied areas for the disease. The prefrontal cortex does not show neuronal death to the same extent as the substantia nigra, although it displays molecular and pathological modifications during the disease process, while also being responsible for the dementia present in a large proportion of Parkinson's disease patients.

Results of the expression experiment showed that the gene FOXO1 had increased expression in the brain tissue samples with known Parkinson's disease. FOXO1 is a transcriptional regulator that can modify the expression of other genes. Further examination of the FOXO1 gene showed that two single-nucleotide polymorphisms (SNPs), or DNA sequence variations, were significantly associated with age at onset of Parkinson's disease.

"Our hypothesis is that FOXO1 acts in a protective manner by activating genes and pathways that fight the neurodegeneration processes," said Dumitriu. "If this is correct, there could be potential to explore FOXO1 as a therapeutic drug target for Parkinson's disease."

###

Follow this link:
BUSM researchers identify role of FOXO1 gene in Parkinson's disease

Aqueous In-Line Cleaner features closed-loop design.

June 29, 2012 - With footprint less than 30 ft, Nanojet(TM) features cycle time of less than 3 minutes, including full chemistry wash, isolation, rinse, final rinse, and dry. Optimal cleaning is assured through Coherent Jets and Progressive Energy Dynamics, which involves increasing energy at each manifold, and vectored jets or fan sprays, depending on cleaning application. Closed-loop system boasts minimal water and chemistry usage. Original Press release Austin American Technology Corp. 12201 Technology Blvd. Austin, TX, 78727 USA Burnet, Texas, USA - AAT's new Nanojet(TM) packs a lot of punch in a small package. As the world's smallest, most powerful inline cleaner, Nanojet(TM) occupies a very small footprint - under 30 ft2 (6'x 44"); yet it outperforms much larger cleaners, with a < 3 minute cycle time including full chemistry wash, isolation, rinse, final rinse and dry. Nanojet(TM) is designed and engineered by Austin American Technology Corporation (AAT), a leading global developer and supplier of production cleaning solutions for the electronics assembly, semiconductor, and other industries.

In the Nanojet, AAT has combined highperformance and advanced, highly efficient cleaning and drying capabilities including PED Wash Technology, ISO & Power Rinsing; and a (Displacement) Jet Dryer.

The AAT Nanojet is completely closed-loop, for maximum chemistry recovery, and substantial operational cost and water savings. Nanojet combines high performance with low cost of ownership, and higher productivity; cycle times tested for processing circuit boards completely washed, rinsed, and dried range from under 3 minutes to 10 minutes.

High-performance cleaning is assured through the Nanojet's unique AAT-engineered features, including Coherent Jets, Progressive Energy Dynamics (PED), a revolutionary system that involves a manifold design with increasing energy at each manifold, and vectored jets or fan sprays depending on the cleaning application.

High throughput is assured through faster and better drying by displacement drying vs. slower evaporative with air knives with higher electrical costs. And, the Nanojet is a 'green' efficient closed-loop system boasting minimal water and chemistry usage, incorporating closed-loop washing and rinsing. This configuration saves chemistry costs, increases DI and carbon bed life, saves water, and saves money and operating costs while at the same time saving the environment.

Overall, the Nanojet is designed to maximize performance while minimizing operating costs - Cost modeling with Cost of Cleaning. This makes Nanojet a powerful cleaning system that saves space, is environmentally responsible, and has a very low cost of ownership.

Thoughtfully-designed access makes the Nanojet easy to maintain and service, and the system can be upgraded in the field. For more information about the Nanojet, visit http://www.aat-corp.com.

About Austin American Technology

Founded in 1986, Austin American Technology (AAT) is an innovative, market-leading company, engineering and manufacturing production and assembly systems for the electronics manufacturing industry. With more than 400 years of collective experience in the electronics and semiconductor industries, AAT's production solutions have included hot gas rework and solder paste testing systems, and introduced the world's first automated stencil cleaner in 1988. During the 1990s, AAT developed batch cleaning systems and were early adopters of closed-loop (zero-discharge) capability. In 2000, AAT became a market leader in in-line cleaning systems with the introduction of the award-winning HYDROJET(TM) series, followed by the MICROJET(TM) inline flip chip cleaner to provide high volume cleaning capability in a small footprint. AAT systems are designed to maximize performance and minimize cost of ownership. For more information, visit http://www.aat-corp.com.

Alloys easily magnetized/demagnetized for specialized applications requiring high permeability, low losses, low residual magnetism - electro-magnetic shielding, transformer laminations/cores, transducers, chokes, relays, solenoids/oscillators, etc.

View original post here:
Aqueous In-Line Cleaner features closed-loop design.

Scientists urge new approaches to plant research

ScienceDaily (June 29, 2012) You'd be amazed at how much you can learn from a plant.

In a paper published this week in the journal Science, a Michigan State University professor and a colleague discuss why if humans are to survive as a species, we must turn more to plants for any number of valuable lessons.

"Metabolism of plants provides humans with fiber, fuel, food and therapeutics," said Robert Last, an MSU professor of biochemistry and molecular biology. "As the human population grows and nonrenewable energy sources diminish, we need to rely increasingly on plants and to increase the sustainability of agriculture."

However, Last and co-author Ron Milo of the Weizmann Institute of Science point out that despite decades of plant genetic engineering, there are relatively few types of commercial products originating from this body of work.

"This is in part because we do not understand enough about the vastly complex set of metabolic reactions that plants employ," Last said. "It's like designing and building a bridge armed only with satellite images of existing bridges."

The authors say that perhaps the best approach is to bring together a variety of disciplines -- not just plant scientists -- to study how plants operate.

They also suggest looking hard at what brought plants to the place they are today -- evolution.

"We think that understanding design principles of plant metabolism will be aided by considering how hundreds of millions of years of evolution has led to well-conserved examples of metabolic pathways," Last said.

One of the amazing aspects of plant metabolism is this: It must continuously strike a balance between evolving to meet an ever-changing environment while maintaining the internal stability needed to carry on life as it knows it.

In addition, the authors point out that plants experiment with specialized (also called secondary) metabolism which can produce novel chemicals that are used to defend against pathogens and herbivores.

See the original post:
Scientists urge new approaches to plant research

Tom Cruise and Katie Holmes: Anatomy of a Split

April 2005: Cruise and Holmes begin dating and make their first public appearance as a couple in Rome.

May 2005: Cruise enthusiastically declares his love for Holmes by famously jumping on a couch on The Oprah Winfrey Show.

October 2005: Cruise and Holmes happily announce they are expecting their first child together.

April 2006: The couple welcomes a daughter. They name her Suri.

October 2006: Cruise and Holmes give the world its first glimpse of Suri by proudly posing with her on the cover of Vanity Fair.

Nov. 18, 2006: Cruise and Holmes tie the knot in a lavish ceremony at the 15th-century Odescalchi Castle in Italy. Jennifer Lopez, Marc Anthony, Will Smith, Jada Pinkett Smith and 7-month-old Suri are among those in attendance.

November 2007: Cruise cheers on Holmes as she runs in the New York City marathon.

January 2009: Holmes accompanies Cruise to the London premiere of Valkyrie.

February 2009: Cruise and Holmes enjoy a family vacation to Disney World.

June 2011: Cruise, Holmes and Suri celebrate Father's Day on a yacht in Miami.

View original post here:
Tom Cruise and Katie Holmes: Anatomy of a Split

Speaker offers insights into Parkinson's

FAIRMONT - It wasn't until celebrities such as Michael J. Fox and Muhammad Ali announced they had Parkinson's Disease that the public began to learn more about this life-altering disease.

While not a terminal illness, Parkinson's does affect the quality of life for those diagnosed.

"About one in 100 people over the age of 60 are diagnosed with Parkinson's Disease," said Rose Wichmann, manager of Struthers Parkinson's Center in Golden Valley. "It goes to two in 100 people over the age of 70. That's more than MS, more than muscular dystrophy and more than ALS-Lou Gehrig's Disease."

Wichmann was in Fairmont on Thursday speaking to a Parkinson's support group at Grace Lutheran Church. She mentioned there are several different types of Parkinson's Disease, and that every person diagnosed has slightly different symptoms.

"Not everyone has the tremors that people associate with Parkinson's," Wichmann said. "We have an acronym called 'TRAP' that lists the four main symptoms, and two or more of these need to be confirmed before receiving a diagnosis."

While tremors are well-associated with Parkinson's, other symptoms are less noticeable, such as rigidity and stiffness in the muscles. There is also the absence or slowing of movements, and posture changes, such as curling over instead of sitting or standing up straight.

"There are about 15 percent of those diagnosed with Parkinson's that never have a tremor," Wichmann said. "But what causes Parkinson's is a group of cells at the base of the brain that produce dopamine. As we age, those cells start to disappear, and about 60 to 80 percent of those disappear before displaying symptoms of Parkinsons."

Dopamine is a chemical that allows the delivery of messages through the brain. Lack of dopamine means signals are not moving as smoothly.

"We say that automatic is broken," Wichmann said. "Those movements you don't even think about, like walking, or rolling over in your sleep. Blinking also goes away, so Parkinson's sufferers have more of a stare. There is a loss of facial expressions because you don't think about if you're going to smile. It's easy for Parkinson's people to be misunderstood because you can't read their facial expressions anymore."

There are also problems with balance.

The rest is here:
Speaker offers insights into Parkinson's

Speaker offers insights into Parkinson’s

FAIRMONT - It wasn't until celebrities such as Michael J. Fox and Muhammad Ali announced they had Parkinson's Disease that the public began to learn more about this life-altering disease.

While not a terminal illness, Parkinson's does affect the quality of life for those diagnosed.

"About one in 100 people over the age of 60 are diagnosed with Parkinson's Disease," said Rose Wichmann, manager of Struthers Parkinson's Center in Golden Valley. "It goes to two in 100 people over the age of 70. That's more than MS, more than muscular dystrophy and more than ALS-Lou Gehrig's Disease."

Wichmann was in Fairmont on Thursday speaking to a Parkinson's support group at Grace Lutheran Church. She mentioned there are several different types of Parkinson's Disease, and that every person diagnosed has slightly different symptoms.

"Not everyone has the tremors that people associate with Parkinson's," Wichmann said. "We have an acronym called 'TRAP' that lists the four main symptoms, and two or more of these need to be confirmed before receiving a diagnosis."

While tremors are well-associated with Parkinson's, other symptoms are less noticeable, such as rigidity and stiffness in the muscles. There is also the absence or slowing of movements, and posture changes, such as curling over instead of sitting or standing up straight.

"There are about 15 percent of those diagnosed with Parkinson's that never have a tremor," Wichmann said. "But what causes Parkinson's is a group of cells at the base of the brain that produce dopamine. As we age, those cells start to disappear, and about 60 to 80 percent of those disappear before displaying symptoms of Parkinsons."

Dopamine is a chemical that allows the delivery of messages through the brain. Lack of dopamine means signals are not moving as smoothly.

"We say that automatic is broken," Wichmann said. "Those movements you don't even think about, like walking, or rolling over in your sleep. Blinking also goes away, so Parkinson's sufferers have more of a stare. There is a loss of facial expressions because you don't think about if you're going to smile. It's easy for Parkinson's people to be misunderstood because you can't read their facial expressions anymore."

There are also problems with balance.

The rest is here:
Speaker offers insights into Parkinson's

Higher Parkinson’s Risk Linked to Certain Solvents

Increased risks for Parkinsons disease have been linked to some solvents. Parkinsons disease is a progressive, degenerative central nervous system disorder that typically affects motor skills and speech, among other functions and, while not fatal, complications can be deadly. The cause is unknown and there is no cure.

Samuel M. Goldman, M.D., M.P.H., of The Parkinsons Institute in Sunnyvale, California, and colleagues, conducted a so-called discordant twin pair design study involving 99 pairs of twins. The study was conducted to determine if exposure to specific solvents is linked to increased risks for Parkinsons disease. Participant interviews involved task-specific and lifetime occupation and hobby questions, said Medical Xpress. The study was published in the Annals of Neurology.

The researchers found that exposure to trichloroethylene (TCE) was associated with a significantly increased risk of Parkinsons disease and saw a trend for significance for exposure to the chemicals perchloroethylene (PERC) and carbon tetrachloride (CCl4). Although the present work focused on occupational exposures, solvents are ubiquitous in the environment, and this is particularly true for those implicated in this studyTCE, PERC, and CCl4, the authors wrote, according to Medical Xpress. Our findings require replication in other populations with well-characterized exposures, but the potential public health implications are considerable, the team authored.

Weve also written that over the past several years, the agricultural pesticide paraquat has been linked to Parkinsons, posing a risk to agricultural workers who toil in fields where the pesticide is sprayed, as well as to people living near the fields.

Other research revealed that people exposed at their workplaces to ziram, maneb, and paraquat tripled their risk of Parkinsons; workplace exposure to both ziram and paraquat nearly doubled Parkinsons risk; and people who worked with either paraquat or the pesticide rotenone were 2.5 times likelier to develop Parkinsons disease.

Another study found that some medications, notably the amphetamines Benzedrine or Dexedrine, used to treat attention deficit hyperactivity disorder (ADHD) and help patients achieve more defined focus and increase clarity and awareness, could also place those patients at risk for Parkinsons disease.

We recently wrote that another study found an association with glyphosate, the active ingredient in Monsatos Roundup, and Parkinsons disease and Parkinsons-related brain disorders. According to a report from the Organic Authority, Roundup is the best-selling pesticide in the world and is the companion chemical application to many of the companys genetically modified seeds including corn, soy, canola and cotton.

According to Digital Journal, this is just the latest study to find a link between glyphosate and Parkinsons-like disorders. For example, a 2011 report published in the journal Parkinsonism Related Disorders, detailed the case of a 44-year-old women with Parkinsons-like symptoms after sustaining long-term chemical exposure to glyphosate for three years as a worker in a chemical factory.

Read more here:
Higher Parkinson’s Risk Linked to Certain Solvents

BUSM researchers identify role of FOXO1 gene in Parkinson's disease

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Jenny Eriksen Leary jenny.eriksen@bmc.org 617-638-6841 Boston University Medical Center

(Boston) A recent study led by researchers at Boston University School of Medicine (BUSM) revealed that the FOXO1 gene may play an important role in the pathological mechanisms of Parkinson's disease. These findings are published online in PLoS Genetics, a peer-reviewed open-access journal published by the Public Library of Science.

The study was led by Alexandra Dumitriu, PhD, a postdoctoral associate in the department of neurology at BUSM. Richard Myers, PhD, professor of neurology at BUSM, is the study's senior author.

According to the Parkinson's Disease Foundation, 60,000 Americans are diagnosed with Parkinson's disease each year and approximately one million Americans are currently living with the disease.

Parkinson's disease is a complex neurodegenerative disorder characterized by a buildup of proteins in nerve cells that lead to their inability to communicate with one another, causing motor function issues, including tremors and slowness in movement, as well as dementia. The substantia nigra is an area of the midbrain that helps control movement, and previous research has shown that this area of the brain loses neurons as Parkinson's disease progresses.

The researchers analyzed gene expression differences in brain tissue between 27 samples with known Parkinson's disease and 26 samples from neurologically healthy controls. This data set represents the largest number of brain samples used in a whole-genome expression study of Parkinson's disease to date. The novel aspect of this study is represented by the researchers' emphasis on removing possible sources of variation by minimizing the differences among samples. They used only male brain tissue samples that showed no significant marks of Alzheimer's disease pathology, one of the frequently co-occurring neurological diseases in Parkinson's disease patients. The samples also had similar tissue quality and were from the brain's prefrontal cortex, one of the less studied areas for the disease. The prefrontal cortex does not show neuronal death to the same extent as the substantia nigra, although it displays molecular and pathological modifications during the disease process, while also being responsible for the dementia present in a large proportion of Parkinson's disease patients.

Results of the expression experiment showed that the gene FOXO1 had increased expression in the brain tissue samples with known Parkinson's disease. FOXO1 is a transcriptional regulator that can modify the expression of other genes. Further examination of the FOXO1 gene showed that two single-nucleotide polymorphisms (SNPs), or DNA sequence variations, were significantly associated with age at onset of Parkinson's disease.

"Our hypothesis is that FOXO1 acts in a protective manner by activating genes and pathways that fight the neurodegeneration processes," said Dumitriu. "If this is correct, there could be potential to explore FOXO1 as a therapeutic drug target for Parkinson's disease."

###

Excerpt from:
BUSM researchers identify role of FOXO1 gene in Parkinson's disease